Sci Trans Med:靶向B细胞新亚群 治疗多发性硬化

2015-10-28 佚名 生物谷

许多研究认为多发性硬化是一种受T细胞控制的疾病,最近也有研究证明在多发性硬化疾病中,T细胞会攻击中枢神经系统覆盖在神经元表面具有保护作用的髓磷脂,对神经细胞造成损伤。 而越来越多的研究发现另一种白细胞类型--B细胞对多发性硬化的发生具有重要促进作用。最近一些临床研究表明用B细胞缺失疗法(BCDT)治疗复发-缓解型多发性硬化有很好疗效。但B细胞究竟如何促进疾病发生以及参与BCDT疗法的分子机制究竟

许多研究认为多发性硬化是一种受T细胞控制的疾病,最近也有研究证明在多发性硬化疾病中,T细胞会攻击中枢神经系统覆盖在神经元表面具有保护作用的髓磷脂,对神经细胞造成损伤。

而越来越多的研究发现另一种白细胞类型--B细胞对多发性硬化的发生具有重要促进作用。最近一些临床研究表明用B细胞缺失疗法(BCDT)治疗复发-缓解型多发性硬化有很好疗效。但B细胞究竟如何促进疾病发生以及参与BCDT疗法的分子机制究竟是什么仍然没有得到很好的阐释。
 
在这项发表在国际学术期刊Science Translational Medicine上的最新研究中,来自蒙特利尔神经研究所和医院的研究人员对多发性硬化疾病背景下B细胞及其与其他免疫细胞发生的复杂相互作用在该疾病发生中发挥的作用进行了深入探讨,取得了突破性进展。
 
在这项研究中,研究人员首先对多发性硬化病人的样本进行了检测,并以健康个体为对照,他们发现在多发性硬化病人样本中GM-CSF产生的B细胞更加常见也更加倾向于发生激活。这一B细胞亚群能够激活免疫系统中髓细胞的促炎症应答,这一现象得到了多发性硬化病人的证实,研究人员发现在进行BCDT治疗后,髓细胞的促炎症活性会下降,说明BCDT可能部分通过降低GM-CSF产生的B细胞数目,进而限制髓细胞和T细胞对疾病的促进作用达到治疗效果。
 
这项研究发现B细胞能够促进多发性硬化疾病中的异常免疫应答,还找到了促进疾病发生的一个B细胞亚群,对于指导多发性硬化治疗具有一定意义。

原文出处:
 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1656677, encodeId=335216566e7c9, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Aug 22 14:20:00 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889647, encodeId=8ef8188964e05, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Wed Apr 20 08:20:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273165, encodeId=b7d712e3165e6, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Fri Oct 30 00:20:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606680, encodeId=f81f16066805d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Oct 30 00:20:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41849, encodeId=e20b4184947, content=感觉什么免疫都可以的样子啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387c1637569, createdName=liusanxin, createdTime=Thu Oct 29 06:25:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41810, encodeId=d76d4181080, content=b一半, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5e91371, createdName=droping, createdTime=Wed Oct 28 20:14:00 CST 2015, time=2015-10-28, status=1, ipAttribution=)]
    2016-08-22 bsmagic9140
  2. [GetPortalCommentsPageByObjectIdResponse(id=1656677, encodeId=335216566e7c9, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Aug 22 14:20:00 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889647, encodeId=8ef8188964e05, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Wed Apr 20 08:20:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273165, encodeId=b7d712e3165e6, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Fri Oct 30 00:20:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606680, encodeId=f81f16066805d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Oct 30 00:20:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41849, encodeId=e20b4184947, content=感觉什么免疫都可以的样子啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387c1637569, createdName=liusanxin, createdTime=Thu Oct 29 06:25:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41810, encodeId=d76d4181080, content=b一半, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5e91371, createdName=droping, createdTime=Wed Oct 28 20:14:00 CST 2015, time=2015-10-28, status=1, ipAttribution=)]
    2016-04-20 jml2009
  3. [GetPortalCommentsPageByObjectIdResponse(id=1656677, encodeId=335216566e7c9, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Aug 22 14:20:00 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889647, encodeId=8ef8188964e05, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Wed Apr 20 08:20:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273165, encodeId=b7d712e3165e6, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Fri Oct 30 00:20:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606680, encodeId=f81f16066805d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Oct 30 00:20:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41849, encodeId=e20b4184947, content=感觉什么免疫都可以的样子啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387c1637569, createdName=liusanxin, createdTime=Thu Oct 29 06:25:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41810, encodeId=d76d4181080, content=b一半, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5e91371, createdName=droping, createdTime=Wed Oct 28 20:14:00 CST 2015, time=2015-10-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1656677, encodeId=335216566e7c9, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Aug 22 14:20:00 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889647, encodeId=8ef8188964e05, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Wed Apr 20 08:20:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273165, encodeId=b7d712e3165e6, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Fri Oct 30 00:20:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606680, encodeId=f81f16066805d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Oct 30 00:20:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41849, encodeId=e20b4184947, content=感觉什么免疫都可以的样子啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387c1637569, createdName=liusanxin, createdTime=Thu Oct 29 06:25:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41810, encodeId=d76d4181080, content=b一半, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5e91371, createdName=droping, createdTime=Wed Oct 28 20:14:00 CST 2015, time=2015-10-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1656677, encodeId=335216566e7c9, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Aug 22 14:20:00 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889647, encodeId=8ef8188964e05, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Wed Apr 20 08:20:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273165, encodeId=b7d712e3165e6, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Fri Oct 30 00:20:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606680, encodeId=f81f16066805d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Oct 30 00:20:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41849, encodeId=e20b4184947, content=感觉什么免疫都可以的样子啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387c1637569, createdName=liusanxin, createdTime=Thu Oct 29 06:25:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41810, encodeId=d76d4181080, content=b一半, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5e91371, createdName=droping, createdTime=Wed Oct 28 20:14:00 CST 2015, time=2015-10-28, status=1, ipAttribution=)]
    2015-10-29 liusanxin

    感觉什么免疫都可以的样子啊

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1656677, encodeId=335216566e7c9, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Mon Aug 22 14:20:00 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889647, encodeId=8ef8188964e05, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Wed Apr 20 08:20:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273165, encodeId=b7d712e3165e6, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Fri Oct 30 00:20:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606680, encodeId=f81f16066805d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Oct 30 00:20:00 CST 2015, time=2015-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41849, encodeId=e20b4184947, content=感觉什么免疫都可以的样子啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387c1637569, createdName=liusanxin, createdTime=Thu Oct 29 06:25:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41810, encodeId=d76d4181080, content=b一半, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5e91371, createdName=droping, createdTime=Wed Oct 28 20:14:00 CST 2015, time=2015-10-28, status=1, ipAttribution=)]
    2015-10-28 droping

    b一半

    0

相关资讯

Neurology:夏天晒太阳较少,多发性硬化发生年龄提前

目的:比较维生素D相关的GC和CYP2R1单核苷酸多态性(SNPs),多发性硬化(MS)风险的 CYP27B1, CYP24A1, 以及HLA-DRB1*1501的SNPs与青少年暴露在维生素D缺乏的环境危险因素与MS发生时的年龄的关系。方法:这项研究包括1161名丹麦MS患者;收集从2009年到2012年所有受试者的生活方式调查问卷和基因分型的血样。从丹麦MS治疗登记处获得患者发病年龄信息。所有

JAMA Neurol:多发性硬化女性能不能纯母乳喂养?

随着科学技术的发展,市面上宣称能替代母乳的奶粉等产品也是层出不穷,尽管价格贵,营养元素丰富,始终无法取代纯母乳的地位。纯母乳的好处啪啦啪啦一大堆,是人类进化史上,物竞天择适者生存的自然选择,能留下发展至今,必有其无法替代的过人之处。对于正常没有疾病的孕产妇,纯母乳喂养除了会导致乳房下垂、女性魅力指数的下降,似乎其他方面的影响是利大于弊。但是现在妊娠期有并发症或合并症的孕产妇越来越多,比如说多发性硬

ECTRIMS 2015:补充维生素D可以改善多发性硬化患者认知功能

最新研究表明,给予多发性硬化(MS)患者补充维生素D治疗可以改善患者认知功能。主要研究老龄化引起的认知和炎症改变的神经科学专家Hala Darwish提出:这项结果提示应该检测MS患者维生素D水平,如果缺乏,就补充维生素D。Darwish在2015年MS治疗和研究的欧洲委员会大会(ECTRIMS)上呈现了她的研究结果。脑受体Darwish教授说,可以从晒太阳或食物中获得的维生素D,在MS的病理生理

Neurology:EB病毒与抽烟与多发性硬化的活跃或进展无关

目的:评估EBV免疫球蛋白G(IgG)抗体水平或者抽烟与单一临床症状(CIS)转化为多发性硬化(MS)或MS进展的相关性。方法:在这项名为BENEFIT临床试验的前瞻性纵向研究中,招募了468名CIS患者,研究人员检测了四个时间点(基线,6月,12月,24月)患者的EBV 的IgG抗体与可替宁(抽烟的生物标志物)水平。预后包括转为临床确诊MS或McDonald MS的时间,复发的人数,扩展残疾状态

Neurology:多发性硬化症患者有合并症时死亡风险显著增加

为比较多发性硬化症(multiple sclerosis,MS)患者的寿命和普通人群的差异,并进一步评估合并症对MS患者预期寿命的影响,加拿大的研究者开展了一项研究,并将结果发表在neurology杂志上。研究者收集了5797名多发性硬化症患者、28807名正常对照个体,对性别、年龄、居住地进行配对。估算每年的死亡率,使用Cox比例风险回归来评估共病状态和死亡率的关系,同时根据年龄分层,对性别、经